Why Are Businesses Choosing OneTest™?
OneTest retails for $189.00 per test. Bulk corporate discounts are available. Other multi-cancer tests can retail for $900 or more.
Studies have shown that cancer screening compliance can improve 10x when accessible testing is offered. OneTest uses a single tube of blood collected when other blood tests are drawn.
OneTest has an industry leading sensitivity at 73% for all cancers (excluding stage IV cancer, which is too late for early detection) with a false positive rate of 1.5%.
Early detection of cancer is vital to save costs on total health spend. Cost of care for later stage cases can be over $138,000 higher than cases caught at an earlier stage.
Despite rising prices, employers expect to cover 82 percent of the cost of employee coverage in 2022, up from 80 percent the year before. (Employer support for family coverage remains at 80 percent of premiums.)
The incidence of cancer is going up. As of 2017, 1 in 2 men and 1 in 3 women will be diagnosed with a life-threatening form of cancer in their lifetime.
Cancer impacts employee productivity and ability to work. Among the roughly 40 percent of cancer survivors who are age 25 to 64, there’s often a feeling of loss of identity and connection with work colleagues.
The Numbers Behind OneTest™ for Cancer
0
+
Types of cancer detectable by OneTest™
0
%
Of cancers are detectable by OneTest
0
%
Employer medical costs attributable to cancer treatment
0
+
Employers have used OneTest™ since 2019
$
100000
+
Difference in treatment cost for cancers caught in later stages
Looking at Multi-Cancer Screening Options?
According to the Society of Human Resource Managers (SHRM) Benefits web page, “self-funded health plans may want to consider providing coverage of new multicancer screening tests, some health specialists recommend…there is a tremendous public health need to identify potentially lethal cancers at earlier stages” (emphasis added) Health Plans Face Decisions Over Preventive Screenings Coverage (shrm.org) (Accessed 10/6/23)
OneTest™ for Corporate Wellness
An Affordable, Accurate Multi-Cancer Early Detection Blood Test Now Available for Your Employees
When included as part of an annual screening and wellness program, OneTest™ helps doctors detect up to 26 cancers at an early stage and reduce healthcare costs. Cancers that are detected in early stages often require less invasive treatment plans and lead to better treatment outcomes.
According to SHRM (the Society for Human Resource Management), cancer is now the top driver of employee healthcare costs.1
One of their recommendations is to cover multi-cancer early detection kits (like OneTest™) to help get patients into treatment or imaging faster to enhance outcomes and save costs. Currently, most health plans only cover four or five cancers and do not screen for cancers of the pancreas, thyroid, kidney, liver, and others. OneTest™ can round out your screening coverage to screen for cancers that would escape your current protocol.
Starting at $189, we offer bulk discounts for businesses as well as flexible testing solutions for all organizations interested in testing.
OneTest™ has an industry-leading screening sensitivity at 73% for all cancers (excluding stage IV cancer, which is too late for early detection) with a false positive rate of 1.5%. Our emphasis is reducing false negatives in cancer screening. Due to the lack of specialized overhead needed for genetic sequencing, OneTest™ continues to be the most affordable MCED on the market and has been trusted by Firefighters, EMS, and HR professionals and the U.S. Military since 2018.
We understand your need for quick and efficient answers. With OneTest™, you can easily apply and utilize our services to obtain results within 7-10 business days after delivery. For shipping and collection services, we offer direct and flexible solutions to your business to make sure that we receive your tests and provide results quickly. Additionally, we offer onsite testing for employees* or convenient screening at one of our 700+ patient service centers offered by My One Medical Source. Once results are delivered, employees can access their results anytime using our online patient portal and can receive a virtual consultation to discuss any next steps for further testing using our telemedicine Rx option.
To discuss how OneTest™ can improve your business, please click below to schedule a cancer screening consultation
*Onsite testing for employees is available at an additional cost, and varies based on the desired location.
References
2. Incident cancers with USPSTF recommended screening. SEER Stat Database: Incidence – SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006-2015.
3. Reddy SR, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. DOI: doi.org/10.1080/03007995.2022.2047536.
4. Business Group on Health. 2023 Large Employers’ Health Care Strategy and Plan Design Survey. August 2022. Available at: https://www.businessgrouphealth.org/resources/2023-large-employers-health-care-strategy-survey-intro.
5. Hubbell E, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-468. DOI: doi.org/10.1158/1055-9965.EPI-20-1134
Incident cancers with USPSTF recommended screening. SEER Stat Database: Incidence – SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006-2015.
Reddy SR, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. DOI: doi.org/10.1080/03007995.2022.2047536.
Business Group on Health. 2023 Large Employers’ Health Care Strategy and Plan Design Survey. August 2022. Available at: https://www.businessgrouphealth.org/resources/2023-large-employers-health-care-strategy-survey-intro.
Hubbell E, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-468. DOI: doi.org/10.1158/1055-9965.EPI-20-1134
Analysis of MarketScan claims database completed by GRAIL, LLC, July 2022. Data on file GA-2022-0085. (PLEASE DO NOT USE THIS ONE)
Copyright © 2023 | OneTest™ for the Early Detection of Cancers | All Rights Reserved.